Extremely prolonged HIV seroconversion associated with an MHC haplotype carrying disease susceptibility genes for antibody deficiency disorders
Alex Padiglione, Eman Aleksic, Martyn French, Alicia Arnott, Kim M Wilson, Emma Tippett, Matthew Kaye, Lachlan Gray, Anne Ellett, Megan Crane, David E Leslie, Sharon R Lewin, Alan Breschkin, Chris Birch, Paul R Gorry, Dale A McPhee, Suzanne M Crowe
Clinical Immunology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2010
Awarded by Australian National Health and Medical Research Council (NHMRC)
Highly purified HIV-1<INF>SF2</INF> gp120 derived from CHO cells, used for the anti-gp120 EIA, was kindly provided by Dr. N Haigwood (Seattle Biomedical Research Institute, Seattle, WA, U.S.A.). This study was supported, in part, by a program grant from the Australian National Health and Medical Research Council (NHMRC) to SMC (358399), and grants from the Australian NHMRC to PRG (433915) and DAM (502617). PRG is the recipient of an Australian NHMRC Level 2 Biomedical Career Development Award. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.